SPIE Journal Paper | 10 September 2024
Luca Giannoni, Marta Marradi, Kevin Scibilia, Ivan Ezhov, Camilla Bonaudo, Angelos Artemiou, Anam Toaha, Frédéric Lange, Charly Caredda, Bruno Montcel, Alessandro Della Puppa, Ilias Tachtsidis, Daniel Rückert, Francesco Saverio Pavone
KEYWORDS: Biopsy, Biological samples, Tissues, Near infrared, Visible radiation, Hyperspectral imaging, 3D modeling, Reflectivity, Statistical analysis, Tumors
SignificanceHistopathological examination of surgical biopsies, such as in glioma and glioblastoma resection, is hindered in current clinical practice by the long time required for the laboratory analysis and pathological screening, typically taking several days or even weeks to be completed.AimWe propose here a transportable, high-density, spectral scanning-based hyperspectral imaging (HSI) setup, named HyperProbe1, that can provide in situ, fast biochemical analysis, and mapping of fresh surgical tissue samples, right after excision, and without the need for fixing, staining nor compromising the integrity of the tissue properties.ApproachHyperProbe1 is based on spectral scanning via supercontinuum laser illumination filtered with acousto-optic tunable filters. Such methodology allows the user to select any number and type of wavelength bands in the visible and near-infrared range between 510 and 900 nm (up to a maximum of 79) and to reconstruct 3D hypercubes composed of high-resolution (4 to 5 μm), widefield images (0.9×0.9 mm2) of the surgical samples, where each pixel is associated with a complete spectrum.ResultsThe HyperProbe1 setup is here presented and characterized. The system is applied to 11 fresh surgical biopsies of glioma from routine patients, including different grades of tumor classification. Quantitative analysis of the composition of the tissue is performed via fast spectral unmixing to reconstruct the mapping of major biomarkers, such as oxy-(HbO2) and deoxyhemoglobin (HHb), as well as cytochrome-c-oxidase (CCO). We also provided a preliminary attempt to infer tumor classification based on differences in composition in the samples, suggesting the possibility of using lipid content and differential CCO concentrations to distinguish between lower and higher-grade gliomas.ConclusionsA proof of concept of the performances of HyperProbe1 for quantitative, biochemical mapping of surgical biopsies is demonstrated, paving the way for improving current post-surgical, histopathological practice via non-destructive, in situ streamlined screening of fresh tissue samples in a matter of minutes after excision.
